JPRN-jRCT2080222884未知3 期
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of The Beta-3 Agonist KRP-114V in Japanese Subjects With Symptoms of Overactive Bladder
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 1,090
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patient showing clear OAB symptoms
排除标准
- •Patients complicated with urinary tract infection, urinary stones, and/or interstitial cystitis
- •Patients with a previous history of recurrent urinary tract infection
- •Patients confirmed to have a post-void residual volume of more than 100 m
研究者
相似试验
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICORSymptoms of overactive bladderEUCTR2008-007087-42-CZAstellas Pharma Europe B.V.1,300
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICORSymptoms of overactive bladderEUCTR2008-007087-42-PTAstellas Pharma Europe B.V.1,300
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICORSymptoms of overactive bladderEUCTR2008-007087-42-DEAstellas Pharma Europe B.V.1,800
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICOREUCTR2008-007087-42-FIAstellas Pharma Europe B.V.1,300
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICORSymptoms of overactive bladderEUCTR2008-007087-42-HUAstellas Pharma Europe B.V.1,300